AstraZeneca said the phase 3 trial for breast cancer drug Lynparza would move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
The change comes after the IDMC concluded Lynparza crossed the superiority boundary for its primary endpoint of invasive disease-free survival versus placebo for patients, and recommended primary analysis now take place, AstraZeneca said on Wednesday.
Lynparza is being jointly developed and commercialised by AstraZeneca and Merck and has been used to treat more than 40,000 patients worldwide.
